The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Aradigm Corporation (ARDM)

NEW YORK--()--The Klein Law Firm announces the commencement of an investigation of Aradigm Corporation (NASDAQCM:ARDM) concerning possible violations of federal securities laws.

On January 9, 2018, the U.S. Food and Drug Administration (“FDA”) released its briefing document for the January 11, 2018 meeting of the Antimicrobial Drugs Advisory Committee to discuss the New Drug Application for Linhaliq™ for the proposed indication of treatment of non-cystic fibrosis bronchiectasis (“NCFB”). The FDA stated that “there were too many uncertainties with regard to duration of treatment, frequency of administration and endpoints to allow for reliance on a single Phase 3 trial” of the drug, and that the FDA recommended Aradigm conduct “two independent trials” to provide evidence supporting the drug’s “overall demonstration of efficacy and safety.”

If you suffered a loss in Aradigm and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/ARDM-Info-Request-Form-244.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

Contacts

The Klein Law Firm
Joseph Klein, Esq.
212-616-4899

Release Summary

The Klein Law Firm announces the commencement of an investigation of Aradigm Corporation

Contacts

The Klein Law Firm
Joseph Klein, Esq.
212-616-4899